AVEO Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
119.03 M |
Public Float |
90.33 M |
AVEO Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.34 |
Market Cap |
$109.62 M |
Shares Outstanding |
160.74 M |
Public Float |
100.48 M |
Address |
One Broadway Cambridge Massachusetts 02142 United States |
Employees | - |
Website | http://www.aveooncology.com |
Updated | 07/08/2019 |
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. The company was founded by Ronald A. |